Neisvac-C

N. meningitidis group C (Strain C11) polysaccharide (de-O-acetylated) conjugated to tetanus toxoid, the active ingredient in Neisvac-C, is a vaccine presented as a vaccine formulation for intramuscular use. It is indicated for prevention of invasive disease caused by Neisseria meningitidis serogroup C in children, adolescents and adults.

GNH USA supplies Neisvac-C as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals and clinics across multiple regions worldwide. The company adheres to stringent quality standards and provides cold-chain logistics to ensure product integrity.

Neisvac-C is a conjugate vaccine that targets the polysaccharide capsule of Neisseria meningitidis serogroup C, providing active immunity against meningococcal disease. - Invasive meningococcal disease (serogroup C): reduces risk of severe infection, sepsis and meningitis. - Nasopharyngeal carriage of serogroup C: helps lower bacterial carriage and transmission in the community. - Travel to endemic regions: offers protection for individuals traveling to areas with documented serogroup C outbreaks.

Following administration, Neisvac-C may be associated with local and systemic reactions, most of which are mild and transient. Common Side Effects: - Injection site pain: mild soreness or tenderness at the injection site. - Redness or swelling: localized erythema or edema around the injection area. - Low‑grade fever: temperature rise up to 38 °C within 24 hours. - Headache: mild to moderate headache occurring shortly after vaccination. - Fatigue: transient tiredness or malaise lasting a day or two. Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare demyelinating neuropathy reported post‑vaccination. - Seizures: infrequent febrile seizures in young children. - Persistent high fever: fever >39 °C lasting more than 48 hours. - Severe local reaction: extensive swelling or necrosis at the injection site.

Healthcare professionals should consider the following precautions when administering Neisvac-C. - Contraindication: avoid use in individuals with documented severe allergic reaction to any vaccine component. - Caution: defer vaccination in persons with acute moderate or severe illness until recovery. - Immunocompromised patients: vaccine may elicit reduced antibody response; assess need for booster doses. - Pregnancy: limited data; weigh potential benefits against unknown risks before vaccinating pregnant women. - Age restrictions: not approved for use in infants younger than 2 months; follow local immunization schedule. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines can interact with other agents that affect the immune system or cause overlapping adverse events. Major Interactions (Avoid): - Live attenuated vaccines: avoid simultaneous administration; separate by at least 4 weeks. - Blood products: postpone vaccination for 3 months after receipt of immunoglobulins or plasma. Moderate Interactions (Monitor Closely): - Immunosuppressive therapy: may diminish vaccine‑induced immunity; monitor antibody levels. - Antipyretics: prophylactic use may mask fever, but does not affect immunogenicity. - Antibiotics: generally no effect, but severe infections may delay vaccination.